AstraZeneca plc (AZN) Rating Reiterated by HSBC
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by stock analysts at HSBC in a report released on Friday. They presently have a GBX 4,700 ($58.22) price target on the biopharmaceutical company’s stock. HSBC’s target price points to a potential upside of 6.71% from the stock’s current price.
A number of other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 4,800 ($59.46) target price on shares of AstraZeneca plc in a report on Thursday, July 21st. Deutsche Bank AG reiterated a “buy” rating on shares of AstraZeneca plc in a report on Friday. Jefferies Group dropped their target price on AstraZeneca plc from GBX 6,000 ($74.32) to GBX 5,600 ($69.37) and set a “buy” rating on the stock in a report on Friday. Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a report on Friday. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.55) target price on AstraZeneca plc and gave the company a “sell” rating in a report on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus price target of GBX 4,951.42 ($61.33).
Shares of AstraZeneca plc (LON:AZN) opened at 4318.00 on Friday. The stock’s 50 day moving average is GBX 4,857.61 and its 200-day moving average is GBX 4,557.17. The stock’s market cap is GBX 54.62 billion. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.